TrialBritish journal of clinical pharmacology2023

Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants.

Maria B Goncalves et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.